
Individual variations in cognitive performance based on fluctuating glucose levels were observed, necessitating further research on the topic.

Individual variations in cognitive performance based on fluctuating glucose levels were observed, necessitating further research on the topic.

Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy.

The researchers found that popularity of videos did not necessarily correlate with the quality of information provided in the video.

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment.

Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.

In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.

A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.

Patrick Vermersch, MD, PhD, University of Lille, France details the adverse events observed in the frexalimab trials and the next steps necessary to establish frexalimab as a standard of care in multiple sclerosis (MS) in the third and final part of an interview.

Explainability, consent, and responsibility are noted as challenges that may hinder implementation of artificial intelligence (AI) in cancer care, according to a new study.

This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.

CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.

These insights, explain the researchers of the study, complement observational studies, which have previously indicated a causal relationship between the 2 diseases.

Clinician and patient interviews indicated satisfaction with the items presented to help describe patient symptoms with different lymphomas.

Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.

For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.

The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.

Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.

Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.

A real-world safety study found that patients treated with brolucizumab had low occurrences of intraocular inflammation, retinal vascular occlusion, and retinal vasculitis.

Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).

Results from a retrospective cohort study analyzing patients with breast cancer bolster reports of an association between radiation therapy and subsequent risks of skin cancers.

Lack of routine testing can lead to tragic consequences for patients with cancer; an analysis raises questions about clinical benefits of digital diabetes management tools; overuse of antibiotics poses risks to patients with a misdiagnosis of pneumonia.

The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.

A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.

On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.

Older patients and patients of sub-Saharan African origin were at an increased risk of late presentation of advanced HIV.

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.

The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).

A study found that cetuximab along or with chemotherapy was an effective option in patients with metastatic colorectal cancer (CRC).

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
